Search

Displaying results 701 - 710 of 4300 in total
  1. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.

  2. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but

  3. Drug

    Cinchocaine

    go.drugbank.com/drugs/DB00527
    ApprovedVet approved

    A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The ...

  4. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.

  5. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.

  6. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib is marketed under the trade name Piqray and is available as oral tablets. … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival

  7. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection.

  8. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    It is available as oral tablets under the market name GEMTESA.

  9. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    Sofosbuvir is also available as a fixed dose combination product with [DB11613] as the commercially available product Epclusa. … Since 2014, sofosbuvir has been available as a fixed dose combination product with [DB09027] (tradename Harvoni) used for the treatment of chronic Hepatitis C.

  10. Drug

    Cefonicid

    go.drugbank.com/drugs/DB01328
    Approved

    A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and sof...